Heart disease and stroke statistics—2019 update: a report from the American Heart Association
Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …
Institutes of Health and other government agencies, brings together in a single document the …
Heart disease and stroke statistics—2018 update: a report from the American Heart Association
EJ Benjamin, SS Virani, CW Callaway… - Circulation, 2018 - Am Heart Assoc
Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …
for Disease Control and Prevention, the National Institutes of Health, and other government …
Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
DP Wilson, TA Jacobson, PH Jones… - Journal of clinical …, 2019 - Elsevier
Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …
NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis
S Tsimikas, S Fazio, KC Ferdinand… - Journal of the American …, 2018 - jacc.org
Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
Heart disease and stroke statistics—2020 update: a report from the American Heart Association
Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports on the most up-to-date statistics related to heart disease, stroke …
Health, annually reports on the most up-to-date statistics related to heart disease, stroke …
[HTML][HTML] The Rotterdam Study: 2016 objectives and design update
A Hofman, GGO Brusselle, SD Murad… - European journal of …, 2015 - Springer
Abstract The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of
Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic …
Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic …
Big data analytics for genomic medicine
Genomic medicine attempts to build individualized strategies for diagnostic or therapeutic
decision-making by utilizing patients' genomic information. Big Data analytics uncovers …
decision-making by utilizing patients' genomic information. Big Data analytics uncovers …
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
K Zhou, SW Yee, EL Seiser, N Van Leeuwen… - Nature …, 2016 - nature.com
Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its
mechanism of action remains unclear. Here the Metformin Genetics (MetGen) Consortium …
mechanism of action remains unclear. Here the Metformin Genetics (MetGen) Consortium …
[HTML][HTML] Lipoprotein (a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene
S Coassin, F Kronenberg - Atherosclerosis, 2022 - Elsevier
Abstract High lipoprotein (a)[Lp (a)] concentrations are one of the most important genetically
determined risk factors for cardiovascular disease. Lp (a) concentrations are an enigmatic …
determined risk factors for cardiovascular disease. Lp (a) concentrations are an enigmatic …